Hospital Arnau de Vilanova

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Bladder cancer3 trials
• Metastatic breast cancer3 trials
• Acute lymphoblastic leukaemia1 trial
• Familial hypercholesterolaemia1 trial
• Heart failure1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial
• Parkinson disease1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 26 trials
• Phase 32 trials
• Phase 1/21 trial

Status

• Completed5 trials
• Active, not recruiting3 trials
• Not yet recruiting2 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• MedSIR2 trials
• Spanish Oncology Genito-Urinary Group2 trials
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• ETOP IBCSG Partners Foundation1 trial
• and 5 more

Running trials

• Not yet recruiting

  Treatment for Ph-negative ALL for Adults up to 65 Years

  NCT07443592· PETHEMA Foundation· Source

  Contact: Carmen Benet, Dr (principal investigator)

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

  Contact: Antonio Llombart Cussac (principal investigator)

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

  Contact: Jose Garcia Sanchez (principal investigator)

• Recruiting

  Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.

  NCT06724159· Spanish Oncology Genito-Urinary Group· Source

  Contact: A responsible person Designated by the Sponsor

• Active, not recruiting

  Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

  NCT05563220· Phase 1/2· Stemline Therapeutics, Inc.· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

  NCT04186013· Phase 2· Spanish Oncology Genito-Urinary Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

  NCT06237309· Phase 2· Regeneron Pharmaceuticals· Source

• Completed

  " Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"

  NCT06032130· University of Valencia· Source

• Completed

  ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL

  NCT04603183· Phase 2· MedSIR· Source

• Completed

  Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer

  NCT04464174· Phase 2· MedSIR· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

  NCT03235544· Phase 2· Incyte Corporation· Source

• Completed

  Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

  NCT03133546· Phase 2· ETOP IBCSG Partners Foundation· Source